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ABSTRACT: 
Haematogenous dissemination of M. tuberculosis (Mtb) is critical to pathogenesis of 
progressive tuberculous infection in animal models. Using a novel phage-based blood assay, 
we report the first concordant evidence in well-characterised immunocompetent human 
cohorts, demonstrating associations of Mtb bacteraemia with progressive phenotypes of latent 
infection and active pulmonary TB respectively. 
 
Introduction: 
Tuberculosis (TB) is the leading cause of death from an infectious disease [1]. The causative 
organism, M. tuberculosis (Mtb) persists within populations by establishing asymptomatic 
latent infection (LTBI); a reservoir for future disease. It is estimated that 5-10% of the LTBI 
population will develop TB prospectively, usually within a 2-year period of acquiring infection 
[2]. The patho-biological mechanisms underpinning progression and severity of active TB are 
poorly understood, however animal studies report early haematogenous Mtb dissemination to 
be an important factor [3]. 
We previously reported a method to detect mycobacteria using phage combined with DNA 
amplification (phage-Recombinase Polymerase Amplification) which exploits the efficiency of 
bacteriophage lysis of mycobacterial cells to relsease DNA for subsequent detection by 
Nucleic acid amplification tests (NAAT) [4]. Using this method, we found evidence of low-grade 
M. bovis bacteraemia (˂102 cells per ml) in the blood of infected cattle, both with and without 
manifestations of overt disease. 
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Here, we report outcomes of a proof-of-concept study applying an adaptation of this method 
(ActiphageTM) to detect human Mtb infection in well-characterised clinical cohorts. Our primary 
objective was to determine whether Mtb can be detected in the blood of immunocompetent 
patients with active pulmonary TB (PTB) and recent contacts with LTBI. A secondary objective 
was to determine the early diagnostic potential of ActiphageTM in PTB. 
 
Methods: 
The study prospectively recruited HIV sero-negative adult patients (aged ≥18 years) into 4 
groups (Table 1): i. Active PTB – positive Xpert-Ultra (Cepheid Inc) or Mtb culture from 
respiratory tract samples with supporting clinical and radiological disease characteristics; ii. 
LTBI – asymptomatic recent PTB contacts identified at contact tracing, with a positive 
QuantiFERON-TB Gold Plus (QFT; Qiagen Inc) and normal chest X-ray (CXR); iii. Non-TB 
illness control group – referred with  suspected PTB but diagnosed with a non-TB illness and 
concomitant microbiological exclusion of Mtb; and iv. Healthy control group – asymptomatic 
and QFT negative with no history of previous TB contact. 
All participants provided blood samples for ActiphageTM testing on recruitment and received 
12-month prospective clinical follow-up.  PTB patients were sampled before commencing anti-
tuberculous treatment. In addition, the LTBI group had QFT and ActiphageTM testing repeated 
after 8-12 weeks to capture IGRA seroconversion events. Participants were retained if they 
were QFT-positive at the second time-point and declined anti-tuberculous chemoprophylaxis. 
Clinical and laboratory teams were blinded to the outcome of ActiphageTM testing and the 
study groups from which samples originated, respectively, until the end of the study. Ethics 
approval was provided by the regional Research and Ethics Committee (REC 15/EM/0109) 
and all participants provided written informed consent at enrolment. 
For the ActiphageTM test (PBD Biotech Ltd), blood (5 ml) was collected into sodium heparin 
tubes (Sarstedt) and stored at room temperature until processing. PBMCs were isolated from 
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2 ml aliquots by: i. Ficoll-Paque Plus (GE Healthcare) using leucosep tubes (Sigma) and ii. 
Hetasep (Stem Cell Technologies) according to the manufacturer’s instructions. PBMCs from 
1 ml of blood were resuspended in 200 µl of ActiphageTM media and samples then transferred 
to ActiphageTM Rapid Tubes and bacteriophage D29 added (20 µl; ~107 pfu) [5]. The samples 
were incubated for 3.5 h at 37°C, centrifuged (13,000 x g; 3 min, room temperature) and the 
flow-through containing the released mycobacterial DNA was further concentrated (Zymo 
DNA Clean and Concentrator-5) and Mtb DNA detected by PCR amplification of IS6110 [6]. 
 
Results: 
Sixty-six participants were recruited (Table 1). Of the 15 participants with PTB, one had 
evidence of miliary disease, with a single cerebral tuberculoma. For the remainder, there were 
no radiological or clinical features of multi-organ involvement. Of the 18 LTBI participants, one 
had QFT seroconversion with the rest persistently QFT positive. All had normal CXR reported 
by a thoracic radiologist. All five participants of the control group with non-TB respiratory illness 
had PTB excluded with bronchoscopy and were treated effectively with antibiotics for 
community acquired pneumonia. 
Eleven of the 15 PTB cohort (73%), including the miliary disease case, and 3 of 18 LTBI 
contacts gave a positive ActiphageTM test (Table 1). The remaining participants with LTBI and 
all participants of both control groups gave a negative ActiphageTM test result. The quantitative 
QFT values and clinical/ CXR characteristics were no different at baseline between 
ActiphageTM-positive and ActiphageTM-negative LTBI participants. 
In the PTB cohort, ActiphageTM-positive results were  associated with sputum smear positivity, 
higher baseline CRP and shorter times to mycobacterial culture (Table 1). In the LTBI group, 
ActiphageTM results were concordant at both time-points and of the three ActiphageTM-positive 
LTBI participants, two developed active, culture-positive PTB after 7 months. Whole genome 
sequence analysis of the Mtb isolates from these cases confirmed origin from their respective 
5 
 
index cases (data not shown). The third ActiphageTM-positive LTBI contact had QFT 
seroconversion but did not develop TB. After 12-months follow up, no ActiphageTM-negative 
participants had developed TB. 
As a clinical diagnostic in symptomatic patients with suspected PTB, ActiphageTM testing had 
a sensitivity and specificity (95 % CI) of 73.3 % (48.1–89.1) and 100 % (56.6–100), 
respectively. When applied to the whole cohort at baseline, specificity (95% CI) for detecting 
PTB was 94.2% (84.1–98.4) with no change in sensitivity.  
 
Discussion: 
This study used phage-based DNA extraction (ActiphageTM) combined with PCR to detect low 
levels of viable Mtb in blood. We demonstrate, for the first time, detection of Mtb in the blood 
of a majority of immunocompetent patients with active PTB and in addition,  a proportion of 
recent TB contacts with LTBI that associated with progression to active TB. Our observations 
provide novel pathological insights of human Mtb infection and support further development 
of ActiphageTM as a blood-based TB diagnostic. 
Recent evidence supports a transitional state of human Mtb infection, termed “incipient TB” – 
characterised by clinical latency but associated with increased risk of active TB progression 
and a host blood transcriptional profile that overlaps with disease [7, 8]. Mechanistic studies 
of early Mtb infection in animal and zebrafish models propose the importance of 
haematogenous seeding in new granuloma formation associated with disease progression [3, 
9, 10]. This study presents the first concordant evidence in humans to support these 
observations. We identified 3 recent PTB contacts with detectable Mtb in blood that persisted 
over 3 months and preceded QFT seroconversion in one participant, supporting the view that 
following inhalation, translocation of Mtb to blood is governed by innate immunity. Two 
participants from this subgroup progressed to TB after 7 months, with neither showing clinical 
or radiological evidence of active TB at their interim 3-month follow-up. Our data suggests that 
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incipient disease associates with, and may be identified by, detecting Mtb in blood during early 
infection. Although our numbers were small, the proportion with detectable Mtb in blood (16%) 
is comparable to the proportion we have previously reported with a TB-like host transcriptional 
profile in blood [8]. This association, together with a detailed characterisation of TB 
progression risk, requires further study. 
The evidence for Mtb bacteraemia during active PTB is unclear. Previous studies applying 
culture and NAAT to blood samples from patients with active TB have been disappointing [11], 
with one study reporting Mtb detectable in the blood of only 21% of HIV positive patients with 
severe miliary disease using Xpert MTB/RIF [12]. The relative inaccessibility of intracellular 
Mtb DNA within circulating PBMCs probably contributes to the poor sensitivity of existing 
methods. Our approach overcomes this by using efficient phage-mediated lysis of Mtb 
released from PBMCs to then allow sensitive detection by NAAT. Our results detected 
circulating Mtb in the majority of active PTB participants with clinical and radiological features 
of single organ disease, suggesting a low grade bacteraemia, below the sensitivity threshold 
of existing techniques. Bacteraemia was associated with greater disease extent, characterised 
by higher bacillary burden, pulmonary cavitation and elevated levels of systemic inflammation. 
In contrast, failure to detect Mtb in the blood of four PTB participants with clinically milder 
disease expression suggests a distinct phenotype of earlier disease characterised by effective 
immune-mediated retention of Mtb in the lung, with any circulating bacteria present at levels 
below the sensitivity threshold of the assay. Together, our data indicates the pathogenesis of 
PTB to associate with a detectable spike in haematogenous Mtb dissemination during two 
phases of Mtb infection – the first during early infection before control has been established, 
reflecting a failure of innate immunity, and later during disease progression, when bacillary 
replication overcomes adaptive immunity. The additional prognostic value of ActiphageTM in 
the phenotypic characterisation and clinical outcome of Mtb infection requires further study, 
including developing methods for quantifying the bacterial load. 
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Although preliminary, this study demonstrates early promise with ActiphageTM as a blood-
based diagnostic tool for infectious PTB to improve earlier diagnosis in patients unable to 
expectorate sputum, and requires investigation in other cohorts with an unmet need including 
extra-pulmonary, paediatric and miliary TB. Developments in the assay to simplify sample 
preparation and molecular detection are required to enhance accessibility for low-resource 
settings; but the advantages of a rapid, low-cost assay that offers a microbiological diagnosis 
in the absence of sputum, are clear. 
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Active Pulmonary TB 
(N=15) 
Non-TB Acute 
Respiratory Illness 
(N=5) 
Pulmonary TB Contacts 
With LTBI 
(N=18) 
Healthy Controls: 
No LTBI 
(N=28) 
ActiphageTM Result 
Positive 
(n=11) 
Negative 
(n=4) 
All Negative 
Positive 
(n=3) 
Negative 
(n=15) 
All Negative 
Male Gender (%) 5 (45.5) 2 (50) 2 (40) 1 (33.3) 10 (55.6) 11 (39.3) 
Age (years; mean ±SD) 31.5 (±13.9) 38.8 (±13.5) 50 (±21.7) 25.3 (±6.4) 54.7 (±12.3) 38.9 (±14.6) 
UK Born (%) 3 (27.2) 1 (25) 2 (40) 1 (33.3) 5 (33.3) 10 (35.7) 
BCG 
Vaccination 
Yes (%)$ 4 (36.4) 2 (50) 2 (40) 2 (66.7) 7 (63.6) 12 (50) 
Unknown (%) 0 0 0 0 4 (26.7) 4 (14.3) 
BMI (kg/m2; mean ±SD) 19.9 (±3.6) 20.9 (±3.0) 25.7 (±5.3) 21.9 (±2.0) 26.2 (±6.9) 27.1 (±8.2) 
TB Disease 
Characteristics 
Smear Positive 7 0 0 0 N/A N/A 
Smear Negative 4 4 0 2 N/A N/A 
Xpert-Ultra 
Grade 
Medium - 
High 
Very Low - 
Low 
All Negative Medium* N/A N/A 
CRP 
(median, IQR) 
63 (36 to 65) 41 (27 to 45.5) 84 (45 to 110) 5 (5 to 5)^ 10 (5 to 13.75) 5 (5 to 10) 
Days to Positive 
Culture 
(median, IQR) 
15 (10.5 to 
22) 
21 (21 to 21) 
1 blood culture 
(S. aureus) 
1 sputum culture 
(M. avium, 6 days) 
26 (23.5 to 
28.5)* 
N/A N/A 
 
Table 1. Demographic and clinical characteristics of all subjects in this study. (BCG, Bacillus Calmette-Guérin; TB, Tuberculosis; BMI, 
Body Mass Index; CRP, C-Reactive Protein; LTBI, Latent TB Infection; S. aureus, Staphylococcus aureus; M. avium, Mycobacterium avium). * 
Data presented are at the time of presentation with TB in two contacts, ^ CRP values refer to data collected at baseline, consistent with the data 
for the other groups, $ Percentages calculated from the subgroup for which BCG status was known. 
